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AObjectives: Our objectives were to determine the prevalence of pulmonary hypertension (PHT) in patients
undergoing aortic valve replacement (AVR) for severe aortic stenosis (AS), characterize risk for PHT, assess
changes in PHT, and analyze its effect on outcomes.
Methods: From January 1996 to July 2010, a total of 4372 patients with severe AS underwent primary AVR.
Right ventricular systolic pressure (RVSP), a surrogate for PHT, was estimated echocardiographically in
2385, the study group. Preoperative RVSP was less than 35 mmHg (low pressure) in 611, 35 to 50 mmHg (mod-
erate PHT) in 1199, and greater than 50 mm Hg (high PHT) in 575. From active follow-up, 10,218 patient-years
were available for survival analysis and 3716 echocardiograms after AVR for assessing RVSP.
Results:Median preoperative RVSP was 41 mm Hg (range, 10-104 mm Hg). Older, more symptomatic female
patients with more comorbidities and tricuspid or mitral regurgitation had higher RVSP. Hospital mortality was
higher in those with higher RVSP (0.9% low presssure, 1.9%moderate PHT, 3.1% high PHT, P ¼ .03), as was
risk of renal (P< .0001) or respiratory failure (P< .0001), sepsis (P ¼ .01), and prolonged hospitalization
(P<.0001). Initial post-AVR RVSP improvement was not maintained but rose to preoperative levels by 3 to
4 years. Long-term survival was worse in patients with higher RVSP (P<.0001): 85% and 63% low pressure;
77% and 45% moderate PHT; and 62% and 31% high PHT at 5 and 10 years, respectively.
Conclusions:Most patients undergoing primary AVR have at least moderate PHT that is not relieved by AVR;
its severity is associated with mortality, serious complications, and worse late survival. PHT severity should be
included in risk assessment before aortic valve intervention. These outcomes suggest that earlier intervention for
AS warrants further study. (J Thorac Cardiovasc Surg 2012;144:1067-74)Supplemental material is available online.Pulmonary hypertension (PHT) is common in patients with
severe aortic stenosis (AS).1-4 Its presence has been
suggested to reflect late-stage cardiac remodeling, and these
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The Journal of Thoracic and Carconsidered high risk. Results after aortic valve replacement
(AVR) are conflicting, however, and have not validated the
contention that PHT increases perioperative risk.5-8 In fact,
most preoperative risk stratification models do not include
the variable describing PHT because its impact on
outcomes has not been consistently supported by previous
analyses.9,10 In addition to the controversy surrounding
the role of PHT in influencing early outcomes, few data
are available on the natural history of PHT after AVR and
on the relation of PHT to long-term survival.
In this study, we assess prevalence of PHT in a large co-
hort of patients undergoing AVR for severe AS, characterize
their risk for PHT, assess postoperative PHT, and analyze its
effect on early and late outcomes after AVR.
PATIENTS AND METHODS
Patients
From January 1996 to July 2010, a total of 4372 patients at Cleveland
Clinic underwent primary AVR with or without coronary artery bypass
grafting for severe AS (aortic valve area<1 cm2) owing to degenerative
or congenital (bicuspid) etiology. Only those receiving bovine pericardial
valve prostheses were included, to control for confounding effects that
device choice may play in outcomes. Patients with any of the following
conditions were excluded from the study: endocarditis, rheumatic etiol-
ogy, previous cardiac surgery, mitral or tricuspid valve procedure fordiovascular Surgery c Volume 144, Number 5 1067
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
PHT ¼ pulmonary hypertension
RVSP ¼ right ventricular systolic pressure
TTE ¼ transthoracic echocardiogram
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Dindications other than functional/ischemic regurgitation, myectomy for
hypertrophic obstructive cardiomyopathy, and concomitant aortic proce-
dures (eg, aneurysm repair). Additional patient characteristics are listed
in Table 1. Preoperative, operative, and postoperative variables were re-
trieved from the prospectively collected Cardiovascular Information Reg-
istry and the echocardiography database, both approved for use in
research by the Cleveland Clinic Institutional Review Board, with patient
consent waived.
Pulmonary Hypertension
Right ventricular systolic pressure (RVSP) was estimated echocardio-
graphically and was used as the surrogate to assess PHT. Preoperative
RVSP was available for 2385 patients; these patients constitute the study
group. RVSP is calculated from the tricuspid valve peak velocity measured
on preoperative transthoracic echocardiogram (TTE) using the equation
(RVSP ¼ 10þ4 [tricuspid valve peak velocity]2). Although RVSP was an-
alyzed as a continuous variable, for descriptive purposes we created 3
groups from the distribution: RVSP less than 35 mm Hg, 35 to 50 mm
Hg, and greater than 50 mm Hg, corresponding to no PHT, moderate
PHT, and severe PHT, respectively (see Table 1).
End Points
In-hospital outcomes. In-hospital outcomes and morbidity were
defined as for the Society for Thoracic Surgeons National Adult Cardiac
Database (see http://www.ctsnet.org/file/rptDataSpecifications252_ 1_For-
VendorsPGS.pdf) and included return to the operating room for bleeding or
tamponade, stroke, renal failure, new requirement for dialysis, prolonged
ventilation, sepsis, and atrial fibrillation.
Postoperative PHT. Postoperative TTE reports were used to assess
postoperative RVSP. Echocardiograms were performed routinely before
discharge and at the discretion of referring physicians during follow-up.
None of the echocardiographic data in this study are based on intraopera-
tive studies. Follow-up echocardiograms were interpreted at as many time
points as available for each patient.
A total of 3716 echocardiographic records on tricuspid valve regurgita-
tion velocity were available for 1792 patients (75% of the total population).
Number of patients and available TTEs at various times postoperatively are
presented in Figure E1.
Survival. Active follow-up data at 2, 5, 10, and 15 years were obtained
through the Cardiovascular Information Registry and supplemented with
information from Social Security’s Death Master File.11,12 A total of
10,218 patient-years of follow-up data were available for analysis. Mean
follow-up time was 4.3  3.4 years.
Data Analysis
Continuous variables are summarized as mean  standard deviation or
as 15th, 50th (median), and 85th percentiles when data are skewed. Simple
comparisons were made using the Wilcoxon rank–sum nonparametric
tests. Categorical data are summarized using frequencies and percentages.
Comparisons were made using c2 tests and Fisher’s exact test where appro-
priate. All analyses were performed using SAS statistical software (version
9.2; SAS Institute, Inc, Cary, NC).1068 The Journal of Thoracic and Cardiovascular SurTime trend of RVSP. Time trend of RVSP was investigated by
linear regression, with date of operation as the independent variable.
Correlates of preoperative RVSP. Multivariable linear regres-
sion was used to identify factors associated with preoperative RVSP.
Variables considered in the analysis are listed in Appendix 1. Bagging
was used for variable selection,13 with automated analysis of 1000 boot-
strap samples. This was followed by tabulating the frequency of occurrence
of single factors and closely related clusters of factors significant at P<.05.
Factors appearing in 50% or more of analyses were retained in the final
parsimonious model. Thereafter, this parsimonious model was augmented
by non–statistically significant factors as indicated in Appendix 1 to trans-
form it into a balancing score.14 This was used to adjust analyses of hospital
outcomes.
Longitudinal trend of RVSP after AVR. To assess the tempo-
ral trend of mean RVSP after the procedure, we analyzed postoperative and
follow-up TTEs longitudinally for change in mean RVSP. Nonlinear
mixed-model regression was used to resolve a number of time phases to
form a temporal decomposition model and to estimate shaping parameters
of each phase. So that the repeated nature of the data (correlated within
each patient) can be accommodated, each phase is independently modu-
lated by a time function with an overall random intercept for all phases.
Longitudinal regression for repeated continuous measurements was used
to implement this temporal decomposition model.
Survival. Overall survival and stratified nonparametric survival esti-
mates were obtained using the Kaplan-Meiermethod. A parametric method
was used to resolve the number of phases of instantaneous risk of death
(hazard function) and to estimate shaping parameters.15 Preoperative
RVSP and the balancing score for RVSP on early and late mortality were
forced into the models to evaluate the unadjusted effect of PHT.
Presentation
Because transformation of measurement scale was often necessary to
meet statistical model assumptions, results are presented as regression
coefficients and their standard errors. Uncertainty is also expressed by
confidence limits or confidence intervals equivalent to 1 standard error
(68%).
RESULTS
The majority of patients in the study had moderate to
severe PHT (n ¼ 1774, 74%). An investigation of trends
in RVSP over time demonstrated no difference in preva-
lence of PHT over the 15-year span of this study. Median
RVSP was 41 mm Hg; its cumulative distribution is shown
in Figure 1.
Older female patients with higher body mass index and
more severe AS, and thosewith left ventricular dysfunction,
functional atrioventricular valve regurgitation, and more
noncardiac comorbidities, had higher levels of RVSP preop-
eratively (Table 2).
Preoperative PHT was associated with worse postopera-
tive outcomes (Table 3). Death, renal failure, and respira-
tory failure occurred more frequently in those with PHT.
Patients with severe PHT also experienced longer intensive
care unit and postoperative hospital stays than those with-
out. Perioperative stroke, bleeding, sepsis, or atrial fibrilla-
tion did not occur statistically significantly more frequently
in those with PHT. After RVSP as a continuous variable had
been assessed and a multivariable balancing score had been
created, the effect of RVSP on outcomes was less apparentgery c November 2012
TABLE 1. Preoperative and intraoperative patient characteristics
Characteristic
Overall
(n ¼ 2385)
Right ventricular systolic pressure
P value
<35 mm Hg
(n ¼ 611)
35-50 mm Hg
(n ¼ 1199)
>50 mm Hg
(n ¼ 575)
Patient
Age (y) 74  10 71  11 74  9.6 76  8.7 <.0001
Female 1066 (45) 230 (38) 548 (46) 288 (50) <.0001
Body mass index
(kg/m2)
28  6.3 (n ¼ 2358) 28  5.4 (n ¼ 604) 28  5.8 (n ¼ 1184) 29  7.8 (n ¼ 570) .08
Hypertension 1802 (76) 422 (69) 909 (76) 471 (82) <.0001
Coronary artery
disease*
1280 (57) (n ¼ 2235) 312 (55) (n ¼ 566) 644 (57) (n ¼ 1126) 324 (60) (n ¼ 543) .3
Prior myocardial
infarction
432 (18) 83 (14) 216 (18) 133 (23) .0001
Prior PCI 244 (10) 57 (9.3) 108 (9.0) 79 (14) .006
Preoperative AF/flutter 260 (12) (n ¼ 2158) 30 (5.5) (n ¼ 545) 113 (10) (n ¼ 1085) 117 (22) (n ¼ 528) <.0001
COPD 388 (16) 73 (12) 182 (15) 133 (23) <.0001
Valve-related
Mean transvalvular
gradient (mm Hg)
48  16 (n ¼ 2283) 49  16 (n ¼ 591) 47  16 (n ¼ 1142) 48  17 (n ¼ 550) .04
Preoperative aortic
valve area (cm2)
0.66  0.14 (n ¼ 2231) 0.68  0.14 (n ¼ 585) 0.67  0.13 (n ¼ 1114) 0.62  0.15 (n ¼ 532) <.0001
Bicuspid aortic valve 629 (26) 229 (37) 305 (25) 95 (17) <.0001
Mitral regurgitation
grade
(n ¼ 2312) (n ¼ 592) (n ¼ 1159) (n ¼ 561) <.0001
0 933 (40) 341 (58) 479 (41) 113 (20)
1þ/2þ 1192 (52) 237 (40) 617 (53) 338 (60)
3þ/4þ 187 (8.0) 14 (2.4) 63 (5.4) 110 (20)
Tricuspid regurgitation
grade
(n ¼ 2384) (n ¼ 611) (n ¼ 1198) (n ¼ 575) <.0001
0 1117 (47) 448 (73) 564 (47) 105 (18)
1þ/2þ 1107 (46) 159 (26) 597 (50) 351 (61)
3þ/4þ 160 (7.0) 4 (0.65) 37 (3.1) 119 (21)
Echocardiographic
Left ventricular
ejection fraction (%)
53  13 (n ¼ 2378) 56  9.7 (n ¼ 610) 54  12 (n ¼ 1196) 47  16 (n ¼ 572) <.0001
Left ventricular mass
index
129  41 (n ¼ 2234) 124  38 (n ¼ 574) 125  40 (n ¼ 1119) 141  44 (n ¼ 541) <.0001
Left atrial volume
indexy
23  13 (n ¼ 2117) 19  9.4 (n ¼ 543) 22  12 (n ¼ 1064) 30  16 (n ¼ 510) <.0001
Operative
CPB time (min) 92  36 87  35 90  35 100  39 <.0001
Aortic clamp time
(min)
73  30 70  27 72  30 79  30 <.0001
Prosthetic valve size
(mm)
22  2.1 23  2.1 22  2.1 22  2.2 <.0001
Concomitant
procedures
CABG 1143 (48) 269 (44) 575 (48) 299 (52) .02
Mitral valve
operation
101 (4.2) 7 (1.1) 29 (2.4) 65 (11) <.0001
Tricuspid valve
operation
91 (3.8) 4 (0.65) 19 (1.6) 68 (12) <.0001
Ablation for AF 215 (9.0) 33 (5.4) 97 (8.1) 85 (15) <.0001
Aorta repair 121 (5.1) 26 (4.3) 61 (5.1) 34 (5.9) .4
Values are reported as number and percentage or mean  standard deviation. PCI, Percutaneous coronary intervention; COPD, chronic obstructive pulmonary disease;
CPB, cardiopulmonary bypass; CABG, coronary artery bypass grafting; AF, atrial fibrillation. *Stenosis>50%. yTo body surface area.
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FIGURE 1. Cumulative distribution of pulmonary hypertension as assessed by right ventricular systolic pressure (RVSP).
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dently associated only with return to the operating room
for bleeding and prolonged postoperative length of stay
(see Table 4).
Overall, compared with preoperative RVSP, average pre-
discharge RVSP initially declined (Figure 2, A). This reduc-
tion was not maintained, however. Very early afterward,TABLE 2. Correlates of preoperative right ventricular systolic
pressure
Variable Estimate ± SE P value
Reliability
(%)*
Demography
Age 6.93  1.57 <.0001 91
Female 1.52  0.478 .002 63
BMI 1.60  0.397 <.0001 85
NYHA class 1.35  0.574 .02 73
Cardiac comorbidity
LV dysfunction 6.67  0.945 <.0001 98
AV peak gradient 6.39  0.681 <.0001 99
Preoperative LA volume indexy 0.111  0.018 <.0001 55
Tricuspid regurgitation severity 5.19  0.263 <.0001 97
Mitral regurgitation severity 0.67  0.273 .01 89
Concomitant mitral valve repair 3.19  1.20 .008 62
Noncardiac comorbidity
COPD 1.85  0.590 .002 83
Preoperative dialysis 4.67  1.96 .02 80
Pharmacologically treated
diabetes
1.19  0.544 .03 67
Bilirubin 1.69  0.534 .002 85
Intercept 25.29  7.74 .001 —
SE, Standard error; BMI, body mass index; NYHA, New York Heart Association; LV,
left ventricular; AV, aortic valve; LA, left atrial;COPD, chronic obstructive pulmonary
disease. *Percent of times factor appeared in 1000 bootstrap models. yTo body sur-
face area.
1070 The Journal of Thoracic and Cardiovascular SurRVSP increased and plateaued. In those with preoperative
PHT (moderate and and high PHT), RVSP rose again after
about 3½ years. In those without preoperative PHT, the late-
phase rise in pressure was not observed during follow-up
(Figure 2, B).
Overall unadjusted estimated survival at 6 months and 1,
2, 5, and 10 years was 93%, 91%, 88%, 75%, and 46%,
respectively. The hazard function resolved to 3 phases: an
early phase up to 6 months, a constant phase, and then
a late phase after 5 years. Survival was lower in patients
with higher RVSP (P< .0001): Unadjusted survival at 1,
5, and 10 years, respectively, was 96%, 85%, and 63%
for RVSP less than 35 mm Hg; 92%, 77%, and 45% forTABLE 3. Hospital outcomes stratified by right ventricular systolic
pressure
Outcome
Right ventricular systolic pressure
P
value
<35 mm Hg
(n ¼ 611)
35-50 mm Hg
(n ¼ 1199)
>50 mm Hg
(n ¼ 575)
No. (%) No. (%) No. (%)
Hospital death 6 (0.98) 23 (1.9) 18 (3.1) .03
Bleeding 20 (3.3) 46 (3.8) 31 (5.4) .15
Stroke 7 (1.1) 21 (1.8) 14 (2.4) .2
Renal failure 23 (3.8) 69 (5.8) 68 (12) <.0001
Renal failure
requiring dialysis
5 (0.82) 18 (1.5) 22 (3.8) .0003
Prolonged ventilation 22 (4.9) 91 (10) 81 (19) <.0001
Sepsis 5 (0.82) 27 (2.3) 19 (3.3) .01
Atrial fibrillation 194 (32) 424 (35) 188 (33) .3
ICU stay (h)* 23/27/72 23/28/94 24/49/144 <.0001
Postoperative stay
(d)*
5.2/6.4/13 5.3/7.6/15 6.3/11/23 <.0001
ICU, Intensive care unit. *15th/50th/85th percentiles.
gery c November 2012
TABLE 4. Effect of right ventricular systolic pressure (continuous
measure) before and after balancing score adjustment
Outcome
Unadjusted
estimate ± SE
P
value
Adjusted
estimate ± SE
P
value
Hospital death 0.029  0.0093 .002 0.0020  0.012 .9
Bleeding 0.0186  0.0071 .008 0.020  0.0086 .02
Renal failure 0.026  0.0054 <.0001 0.0061  0.0067 .4
Prolonged
ventilation
0.035  0.0052 <.0001 0.0073  0.0063 .2
Sepsis 0.016  0.0097 .09 0.00074  0.012 >.9
ICU stay (h)* 1.45  0.19 <.0001 0.24  0.22 .3
Postoperative
stay (d)*
0.11  0.0108 <.0001 0.027  0.012 .03
Hospital stay (d)* 0.16  0.013 <.0001 0.021  0.015 .17
SE, Standard error; ICU, intensive care unit. *Linear regression.
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RVSP greater than 50 mm Hg (Figure 3). As is clear from
Figure 3, RVSP level stratifies patients predominantly
within the first year after AVR. This is corroborated by
the balancing-score–adjusted analysis, which demonstrated
an increase in early risk (coefficient, 0.013  0.0059;
P ¼ .02; a hazard ratio of 1.14 per 10 mm Hg, or a 14% in-
creased risk) but probably not of late risk (coefficient,
0.0052  0.0036; P ¼ .15; a hazard ratio of 1.053 per 10
mm Hg, or a 5.3% increased risk). Five-year predicted sur-
vival according to preoperative RVSP is shown in Figure 4.
DISCUSSION
Principal Findings
Our analysis confirms that PHT is common (74%) in pa-
tients undergoing primary AVR for severe AS. The stron-
gest risk factors for PHT are older age, obesity, more
advanced aortic valve disease and ventricular dysfunction,
associated atrioventricular valve disease, and comorbid pul-
monary, respiratory, and liver disease. PHT is associated
with worse perioperative outcomes. After AVR, it initially
declines but then progresses in patients who had it preoper-
atively and is associated with decreased late survival.
Prevalence and Risk Factors
Prevalence of PHT in patients with severe AS ranged
from 29% to 74% in this study. Variability is in part due
to inconsistent definitions of PHT.16 We used TTE-
assessed RVSP as a continuous variable to identify the rela-
tionship between PHT and outcomes. Others have used
a combination of right heart catheterization assessments
or echocardiograms. In previous studies, patients have
been artificially separated into groups on the basis of these
measurements. Although RVSP is a calculated value, use of
echocardiography allowed for a consistent measure that we
could follow over time. With complete echocardiographic
data available for more than 75% of our patients, the current
study is the largest of its kind to date.The Journal of Thoracic and CarPHT is complex and can be attributable to multiple
causes, classified as arterial PHT, PHT secondary to heart
disease, PHT secondary to hypoxic lung disease, PHT sec-
ondary to thromboembolic disease, or miscellaneous.17 Al-
though this study lacks the detail to differentiate various
causes, most patients in this large cohort have PHT from
cardiac causes or a combination of cardiac and other causes,
an entity that is poorly understood.18 Current guidelines for
treating AS generally recommend delaying surgery until pa-
tients with severe AS begin having symptoms or objective
findings consistent with development of late-phase cardiac
remodeling (ie, left ventricular dysfunction or a positive re-
sult from a stress test). Given the current state of practice, it
is not surprising that PHT is so prevalent or that its risk fac-
tors include higher transvalvular gradients, left ventricular
dysfunction, increased left atrial diameter, older age, and
severe dysfunction of other major organ systems.
PHT and Early Outcomes
There is little question that patients with severely symp-
tomatic AS do better with AVR than without, and this has
been confirmed in patients with severe PHT as well.4,6
Understanding the effect of PHT on surgical risk, however,
has been challenged by inadequately powered studies and
lack of PHT variables in larger databases. Melby and
colleagues8 demonstrated a significant difference in perio-
perative mortality among patients with (9.7%) and without
(5.4%) PHT, but multivariable analysis did not show PHT
to independently predict worse outcome. Similarly, overall
mortality and several other complications were worse in pa-
tients with higher RVSP in our study. In multivariable analy-
sis, however, the effect of RVSPwas not as strong. PHT does
not develop in isolation. Its etiology is multifactorial, and as-
sociated comorbid conditionsmay contribute to surgical risk.
By the time severe PHT develops in patients with severe AS,
they may be at increased surgical risk for many reasons.
Transcatheter AVR therapies may provide a less-invasive
option for patients with late-stage disease and have been
shown to be superior to medical management for inoperable
candidates. Transcatheter AVR has not been shown to be su-
perior to surgical AVR, however, in eligible high-risk pa-
tients. In a Canadian multicenter analysis of transcatheter
AVR, PHT was predictive of both 30-day (odds ratio,
2.09) and late (hazard ratio, 1.88) mortality.19 Because du-
rability of transcatheter AVR devices is less well understood
than that of standard surgical valves, understanding the role
PHT plays in prognosis may prove important during the pre-
operative selection process.
PHTAfter AVR
Prior studies have demonstrated reduced pulmonary
pressures after AVR.5,8 Roithinger and colleagues20 showed
that the drop in pulmonary pressures was greater in those re-
ceiving larger valves. Melby and colleagues8 showed thatdiovascular Surgery c Volume 144, Number 5 1071
FIGURE 2. Trends in right ventricular systolic pressure (RVSP) after aortic valve replacement. Symbols represent data groupedwithin time frames, without
regard for repeated assessment, simply to provide crude verification of model fit. Larger symbols depict preoperative mean values. preop, Preoperative.
A, Entire cohort. B, Stratified by preoperative RVSP.
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values at a mean follow-up of more than 3 years, but echo-
cardiographic data were available for only 28% of survi-
vors. Although we demonstrated an initial drop in RVSP
similar to that found in other studies, this reduction was
not maintained. During follow-up, 2 increasing phases of
pressure rise were seen: 1 early after surgery and the other
at about 3½ years postoperatively.When stratified by preop-
erative RVSP, patients without PHT did not experience the
late increase (see Figure 2, B).
It has been suggested that diastolic dysfunction is
a major determinant of PHT in patients with AS.21072 The Journal of Thoracic and Cardiovascular SurThis study demonstrated persistent increases in PHT
over time, especially when the process has already be-
gun. Again, this indicates that many of these patients
are possibly being treated too late in the disease
process.
PHT and Late Outcomes
We21 have previously demonstrated that presence of se-
vere left ventricular hypertrophy is associated with de-
creased survival after AVR in a similar cohort of patients.
This effect was magnified by severity of AS and small pros-
thesis size. These findings suggest that relying on symptomsgery c November 2012
FIGURE 3. Survival after aortic valve replacement stratified by preoperative right ventricular systolic pressure (RVSP). Each symbol represents a death,
vertical bars are 68% confidence limits representing 1 standard error, and numbers below horizontal axis are patients remaining at risk.
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formed before irreversible myocardial changes occur. Simi-
larly, we have demonstrated in this study that severity of
preoperative PHT, another indication of late myocardial re-
modeling, is associatedwithworse late outcomes after AVR.
Clinical Implications
Although RVSPmay decrease soon after AVR, once PHT
has developed in patientswith severeAS the processmay not
be reversible and may explain why late outcomes are worseFIGURE 4. Predicted 5-year survival after aortic valve replacement as asses
estimate enclosed within dashed 68% confidence limits representing 1 stand
The Journal of Thoracic and Carin those with higher RVSP. Understanding a patient’s
long-term prognosis is an important factor in the decision-
making process before AVR and pertains not only to indica-
tions for proceeding but also to approach and prosthesis
selection. It is important to consider the severity of
irreversible changes manifest as PHT when evaluating pa-
tients for aortic valve intervention. Lack of PHT regression
and evidence of its progression, aswell as reduced long-term
survival, in patients who have undergone AVR suggest that
earlier intervention for AS should be studied more closely.sed by right ventricular systolic pressure (RVSP). Solid line is parametric
ard error.
diovascular Surgery c Volume 144, Number 5 1073
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APPENDIX 1. VARIABLES CONSIDERED IN
MULTIVARIABLE ANALYSES*
Demography
Age (years),* gender,* height (cm), weight (kg), body
surface area (m2), body mass index (kg/m2)*
Preoperative Status
New York Heart Association functional class (I-IV),*
Canadian Angina Class (I-IV), emergency surgery, syn-
cope, dyspnea on exertion, shortness of breath, paroxysmal
nocturnal dyspnea,* orthopnea*
Ventricular Dysfunction
Left ventricular dysfunction grade (1 ¼ none, 2 ¼ mild,
3 ¼ moderate, 4 ¼ moderately severe, 5 ¼ severe),* prior
myocardial infarction
Aortic Valve
Pathology: Regurgitation, stenosis
Function/size: Orifice area (cm2), mean gradient
(mm Hg), peak gradient (mm Hg)*
Etiology: Degenerative
Other Valve Pathology
Tricuspid regurgitation, mitral regurgitation*
Cardiac Comorbidity
Preoperative atrial fibrillation*; number of coronary sys-
tems with more than 50% stenosis*; stenosis of the left an-
terior descending coronary artery, left main trunk, right
coronary artery, left circumflex coronary artery (>50%,
any); family history of coronary artery disease; ventricular
arrhythmia; complete heart block*; history of endocarditis;
heart failure*
Noncardiac Comorbidity
Treated diabetes,* hypertension,* stroke,* peripheral
arterial disease, chronic obstructive pulmonary disease,*
renal failure, blood urea nitrogen (mg/dL),* creatinine
(mg/dL),* bilirubin (mg/dL),* cholesterol (total, high-
density lipoprotein, low-density lipoprotein, [mg/dL],
triglycerides (mg/dL), hematocrit (%)*
Left Atrium
Diameter (cm), volume (cm3), volume index*
Left Ventricle
Morphology: Inner diameter in diastole (cm), inner diam-
eter in systole (cm), diastolic volume (mL), systolic volume
(mL), diastolic volume index (mL/m2), systolic volume
index (mL/m2), dilated left ventricle
Function: Fractional shortening, ejection fraction (%),*
relative wall thickness (wall stress)
Mass: Mass (g), mass index (g/m2), posterior wall thick-
ness (cm),* septal thickness (cm)
Details of AVR
Valve size, in vitro effective orifice area, ratio: valve area/
body surface area, ratio: effective orifice area/body surface
area, internal valve area, efficiency: effective orifice area/
internal valve area
Concomitant Procedure
Coronary artery bypass grafting,* mitral valve repair* or
replacement, tricuspid valve repair, atrial fibrillation, septal
myectomy
Experience
Date of operation*
*Variables included in RVSP balancing score.
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FIGURE E1. Number of patients with echocardiograms available at and beyond various time points, and number of echocardiograms available for
analysis.
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